| Metric | Current Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥9.2B | ¥11.5B | -20.4% |
| Operating Income / Operating Profit | ¥-1.0B | ¥0.4B | -79.5% |
| Ordinary Income | ¥-0.9B | ¥0.1B | -95.1% |
| Net Income / Net Profit | ¥-0.9B | ¥2.9B | -132.5% |
| ROE | -1.1% | 3.4% | - |
FY2026 Q1 results started harshly with Revenue ¥9.2B (YoY -¥2.3B -20.4%), Operating Loss ¥1.0B (YoY -¥1.4B -79.5%), Ordinary Loss ¥0.9B (YoY -¥1.0B -95.1%), and Net Loss ¥0.9B (YoY -¥3.8B -132.5%). The Pharmaceuticals segment (Pharmaceuticals Business), the core business, remained resilient with Revenue ¥8.6B (-13.2%) and maintained Operating Income ¥1.6B, but the Infection Control segment (Infection Control Business) plunged to Revenue ¥0.6B (-65.0%) and continued an Operating Loss of ¥0.4B, making it difficult to absorb corporate-level expenses of ¥2.1B and leading to an operating-stage loss. Gross margin fell to 54.6% (from 59.0% YoY, -4.4pt) and operating margin declined to -10.7% (from +3.8% YoY, -14.5pt), indicating significant deterioration in profitability. A non-recurring gain of ¥3.6B (gain on sale of investment securities ¥3.5B) was recorded but was insufficient to offset the operating loss, resulting in a final loss.
[Revenue] Revenue ¥9.2B (YoY -20.4%) contracted by ¥2.3B overall due to a substantial decline in the Infection Control business and a double-digit decline in the Pharmaceuticals business. By segment, Pharmaceuticals recorded Revenue ¥8.6B (93.8% of total, YoY -13.2%) and Operating Income ¥1.6B (margin 18.6%), though Operating Income declined sharply YoY by -49.0%. Infection Control fell rapidly to Revenue ¥0.6B (6.1% of total, -65.0%) with an Operating Loss of ¥0.4B (margin -73.2%); while the deficit narrowed 33.9% YoY, the absolute loss remains large. Other businesses posted Revenue ¥0.0B and Operating Loss ¥0.1B and are immaterial. After allocation of corporate expenses of ¥2.1B, consolidated Operating Loss was ¥1.0B; negative operating leverage was pronounced due to insufficient absorption of fixed costs amid revenue decline. The decline in gross margin appears attributable to a worse product mix and pricing pressure.
[Profit & Loss] Against an Operating Loss of ¥1.0B, non-operating income was ¥0.1B (interest income ¥0.1B, compensation income ¥0.0B) and non-operating expenses were ¥0.1B (foreign exchange losses ¥0.0B, etc.), resulting in an Ordinary Loss of ¥0.9B. A special gain of ¥3.6B (gain on sale of investment securities ¥3.5B) was recorded and special losses were ¥0.0B, producing a pre-tax loss of ¥0.9B. Income taxes were ¥0.0B (tax adjustment -¥0.0B, resulting in an effective tax burden of almost zero), yielding a Net Loss of ¥0.9B. Comprehensive income was -¥0.9B, with Other Comprehensive Income ¥0.0B (foreign currency translation adjustment ¥0.1B, valuation differences on available-for-sale securities -¥2.3B) having limited effect. Due to the operating-stage loss and the temporary nature of the special gain, earnings quality is weak. In conclusion, the company is in a revenue-decline and operating-loss position; after the special gain, the result remains a final loss — a downturn of declining revenue and declining profit.
The Pharmaceuticals segment reported Revenue ¥8.6B (93.8% of total) and Operating Income ¥1.6B (margin 18.6%), down YoY -49.0% in Operating Income. It is the company’s profit source but profitability fell significantly from 31.8% last year. The Infection Control segment recorded Revenue ¥0.6B (6.1% of total) and an Operating Loss ¥0.4B (margin -73.2%), with Revenue down from ¥1.6B and Operating Loss down from ¥0.6B YoY (absolute deficit narrowed by 33.9%). Other businesses are minor with Revenue ¥0.0B and Operating Loss ¥0.1B. Corporate expenses of ¥2.1B were allocated, and profits from the profitable segment could not absorb the losses of the unprofitable segment and corporate expenses, causing the operating loss.
[Profitability] Operating margin -10.7% (from +3.8% YoY, -14.5pt), Net margin -10.4% (from +25.4% YoY, -35.8pt) — substantial deterioration. ROE -1.1% (prior year not stated), investment efficiency declined sharply due to the return to loss. Gross margin 54.6% (from 59.0% YoY, -4.4pt) reflects product mix deterioration and price pressure. SG&A ratio 65.3% (from 55.1% YoY, +10.2pt) indicates the relative persistence of fixed costs amid revenue decline and the impact of negative operating leverage. [Cash Quality] DSO 611 days (from 777 days YoY, improved -166 days), DIO 1,697 days (from 718 days YoY, worsened +979 days), CCC 2,046 days (from 1,323 days YoY, worsened +723 days) — inventory and work-in-progress stagnation is severe and the working capital cycle deteriorated significantly. Cash and deposits ¥33.3B provide stability on a free-cash-flow basis but declined ¥9.2B from ¥42.6B prior year. [Investment Efficiency] Total asset turnover 0.08x (from 0.09x prior year) remains low and asset efficiency has worsened. [Financial Soundness] Equity Ratio 73.0% (from 69.4% YoY, +3.6pt), Current Ratio 413.8% (from 336.1%), Quick Ratio 382.4% (from 323.7%) — high liquidity maintained and a conservative financial base. D/E Ratio 0.37x (from 0.44x) indicates low interest-bearing debt burden. Retirement benefit liabilities ¥6.2B are 7.5% of net assets and relatively small.
Operating Cash Flow data were not disclosed, but funding trends can be inferred from BS movements. Cash and deposits ¥33.3B decreased ¥9.2B YoY, suggesting funding for operating and investing activities. Inventories rose significantly to ¥5.7B (from ¥3.1B YoY, +¥2.6B, +83.5%), with WIP ¥8.5B (from ¥8.0B, +¥0.5B) and Finished Goods ¥5.7B (from ¥3.1B, +¥2.6B) showing marked stagnation. Accounts receivable ¥15.3B (from ¥24.5B YoY, -¥9.2B, -37.4%) declined substantially, reflecting demand weakness and improved collections. Accounts payable ¥3.0B (from ¥2.7B, +¥0.3B) and bonus reserves ¥0.6B (from ¥2.5B, -¥1.9B) indicate a reduction in operating liabilities, while working capital enlarged due to inventory increases. The special gain ¥3.6B on sale of investment securities contributed to cash generation, but overall cash position weakened due to operating losses and working capital deterioration. Inventory reduction and profitability recovery will be key to future cash generation.
With an Operating Loss of ¥1.0B, recurring earning power is weak; the ¥0.1B difference to the Ordinary Loss of ¥0.9B reflects minor non-operating income/expense items. The special gain ¥3.6B (gain on sale of investment securities ¥3.5B) is temporary, and non-operating income ¥0.1B (1.1% of Sales) largely reflects recurring items such as interest income. Pre-tax loss ¥0.9B resulted in almost zero effective tax burden (tax adjustment -¥0.0B), yielding Net Loss ¥0.9B. The divergence between Ordinary Income and Net Income is small (difference ¥0.0B); the tax effect adjusted the impact of special items. Comprehensive income -¥0.9B aligns closely with Net Income; Other Comprehensive Income ¥0.0B (foreign currency translation adjustment ¥0.1B and valuation differences on securities -¥2.3B offset) had limited impact. Dependence on temporary special gains amid operating losses weakens earnings quality and sustainability. Declining gross margin and rising SG&A ratio indicate deteriorating underlying profitability; improvements require product mix/pricing measures and fixed-cost reductions.
Full Year (FY) forecast remains Revenue ¥72.0B (YoY +12.5%), Operating Income ¥5.0B (+8.9%), Ordinary Income ¥5.2B (+7.7%), Net Income ¥5.5B (EPS ¥10.95), Dividend ¥0.0 maintained. Q1 Revenue ¥9.2B (progress rate 12.7%) lags the standard 25% pace by -12.3pt, and the Operating Loss ¥1.0B shows a negative progress rate and significant divergence from forecast. Main causes are the sharp decline in Infection Control and reduced profitability in Pharmaceuticals plus insufficient fixed-cost absorption. To achieve the full-year forecast, the company needs Revenue ¥62.8B in the remaining three quarters (Q2 onward quarterly average ¥20.9B, +228% vs Q1) and Operating Income ¥6.0B (i.e., ¥2.0B per quarter Q2 onward and turning to operating profit from Q1), which presumes substantial recovery via inventory reduction, SG&A restraint, and gross margin improvement. Q1’s sluggish progress is notable and the possibility of forecast revision should be monitored.
Q1 dividend ¥0.0, Full Year forecast dividend ¥0.0 — maintaining no dividend. Payout Ratio is not calculable due to the loss. Although Cash and deposits ¥33.3B (40.3% of net assets) are held, prioritizing preservation of internal funds given operating losses and working capital deterioration is reasonable. Resumption of dividends requires operating profitability and stable cash generation; progress in profitability recovery and inventory reduction would be triggers to reconsider dividend policy. No share buyback has been disclosed and Total Return Ratio is not implemented.
Business concentration risk: Pharmaceuticals accounts for 93.8% of Revenue, indicating high reliance on specific products and channels. This increases vulnerability to demand fluctuations and price competition; the -4.4pt decline in gross margin and -49.0% drop in Operating Income underscore that portfolio concentration amplifies volatility.
Inventory and WIP stagnation risk: Inventories ¥5.7B (YoY +83.5%) and DIO 1,697 days (YoY +979 days) show marked stagnation. Composed of Finished Goods ¥5.7B, WIP ¥8.5B, and Raw Materials ¥5.2B, there are risks of valuation losses, obsolescence, and prolonged cash lock-up. The extreme CCC of 2,046 days will continue to burden working capital.
Structural deterioration of profitability risk: Operating margin -10.7% (from +3.8% YoY, -14.5pt), Net margin -10.4% (from +25.4% YoY, -35.8pt) — significant deterioration. If SG&A ratio remains high at 65.3% and Gross margin stays depressed at 54.6%, recovery to profitability may be delayed and full-year targets could be missed.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | -10.7% | – | – |
| Net Margin | -10.4% | – | – |
Both operating and net margins are negative; industry comparative data are unavailable, but given the return to loss, the company’s profitability likely lags materially.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | -20.4% | – | – |
Revenue declined -20.4% YoY indicating significant negative growth. Industry comparatives are not available, but the sharp decline in Infection Control and contraction in the core Pharmaceuticals business have worsened the growth trend.
※ Source: Company aggregation
The sharp decline in Infection Control (Revenue -65.0%) and reduced profitability in Pharmaceuticals (Operating Income -49.0%) led to an operating loss; achieving the full-year forecast requires a substantial rebound from Q2 onward. Q1 progress rate 12.7% (standard 25% comparison -12.3pt) is notably delayed; execution on inventory reduction, SG&A cuts, and gross margin improvement are monitoring points.
Inventories ¥5.7B (+83.5%), DIO 1,697 days (+979 days), CCC 2,046 days (+723 days) — the working capital cycle has deteriorated extremely. WIP ¥8.5B and Finished Goods ¥5.7B stagnation raise valuation loss risk and prolong cash lock-up, inhibiting operating cash flow generation. Progress in inventory normalization is key to profitability recovery and cash generation.
Current liquidity and balance-sheet strength are conservative with Current Ratio 413.8%, Equity Ratio 73.0%, and Cash and deposits ¥33.3B; short-term liquidity resilience is high. The special gain ¥3.6B (gain on sale of investment securities) is temporary; sustained growth requires operating profitability and persistent cash generation.
This report is an analytical financial document automatically generated by AI analyzing XBRL financial statement data. It is not a recommendation to invest in specific securities. Industry benchmarks are reference information aggregated by the Company based on public financial statements. Investment decisions should be made at your own responsibility and, where appropriate, after consulting a professional advisor.